Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUXEDO-5
2024-512369-14-00Phase 2Withdrawn
- Sponsor
- MEDSIR
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by MEDSIR. Primary endpoint: Intracranial objective response rate (ORR-IC). Planned start Jul 2025; status: withdrawn.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on 2024-512369-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512369-14-00.